Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?

Published

Journal Article

The widely used antiretroviral agent tenofovir disoproxil fumarate has been associated with proximal tubular injury and decreased glomerular filtration rate in HIV-infected individuals. Phase 3 trials of a new prodrug, tenofovir alafenamide, suggest a lower potential for kidney injury.

Full Text

Duke Authors

Cited Authors

  • Wyatt, CM

Published Date

  • January 2016

Published In

Volume / Issue

  • 89 / 1

Start / End Page

  • 5 - 6

PubMed ID

  • 26759035

Pubmed Central ID

  • 26759035

Electronic International Standard Serial Number (EISSN)

  • 1523-1755

Digital Object Identifier (DOI)

  • 10.1016/j.kint.2015.11.014

Language

  • eng

Conference Location

  • United States